271 related articles for article (PubMed ID: 19524120)
1. Complex prolactin crosstalk in breast cancer: new therapeutic implications.
Carver KC; Arendt LM; Schuler LA
Mol Cell Endocrinol; 2009 Aug; 307(1-2):1-7. PubMed ID: 19524120
[TBL] [Abstract][Full Text] [Related]
2. The role of prolactin and growth hormone in breast cancer.
Wennbo H; Törnell J
Oncogene; 2000 Feb; 19(8):1072-6. PubMed ID: 10713692
[TBL] [Abstract][Full Text] [Related]
3. Dense collagen-I matrices enhance pro-tumorigenic estrogen-prolactin crosstalk in MCF-7 and T47D breast cancer cells.
Barcus CE; Holt EC; Keely PJ; Eliceiri KW; Schuler LA
PLoS One; 2015; 10(1):e0116891. PubMed ID: 25607819
[TBL] [Abstract][Full Text] [Related]
4. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
Huang Y; Li X; Jiang J; Frank SJ
Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
[TBL] [Abstract][Full Text] [Related]
5. Progesterone receptors (PR) mediate STAT actions: PR and prolactin receptor signaling crosstalk in breast cancer models.
Leehy KA; Truong TH; Mauro LJ; Lange CA
J Steroid Biochem Mol Biol; 2018 Feb; 176():88-93. PubMed ID: 28442393
[TBL] [Abstract][Full Text] [Related]
6. Prolactin enhances insulin-like growth factor I receptor phosphorylation by decreasing its association with the tyrosine phosphatase SHP-2 in MCF-7 breast cancer cells.
Carver KC; Piazza TM; Schuler LA
J Biol Chem; 2010 Mar; 285(11):8003-12. PubMed ID: 20080972
[TBL] [Abstract][Full Text] [Related]
7. Mechanistic aspects of crosstalk between GH and PRL and ErbB receptor family signaling.
Frank SJ
J Mammary Gland Biol Neoplasia; 2008 Mar; 13(1):119-29. PubMed ID: 18236142
[TBL] [Abstract][Full Text] [Related]
8. Breast Cancer and Prolactin - New Mechanisms and Models.
Clevenger CV; Rui H
Endocrinology; 2022 Oct; 163(10):. PubMed ID: 35922139
[TBL] [Abstract][Full Text] [Related]
9. New mechanisms for PRLr action in breast cancer.
Clevenger CV; Gadd SL; Zheng J
Trends Endocrinol Metab; 2009 Jul; 20(5):223-9. PubMed ID: 19535262
[TBL] [Abstract][Full Text] [Related]
10. Expression of prolactin and its receptor in human breast carcinoma.
Reynolds C; Montone KT; Powell CM; Tomaszewski JE; Clevenger CV
Endocrinology; 1997 Dec; 138(12):5555-60. PubMed ID: 9389544
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathways: blockade of the PRLR signaling pathway as a novel antihormonal approach for the treatment of breast and prostate cancer.
Damiano JS; Wasserman E
Clin Cancer Res; 2013 Apr; 19(7):1644-50. PubMed ID: 23515410
[TBL] [Abstract][Full Text] [Related]
12. Crosstalk between PRLR and EGFR/HER2 Signaling Pathways in Breast Cancer.
Kavarthapu R; Anbazhagan R; Dufau ML
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572912
[TBL] [Abstract][Full Text] [Related]
13. A favorable role of prolactin in human breast cancer reveals novel pathway-based gene signatures indicative of tumor differentiation and favorable patient outcome.
Hachim IY; Shams A; Lebrun JJ; Ali S
Hum Pathol; 2016 Jul; 53():142-52. PubMed ID: 26980025
[TBL] [Abstract][Full Text] [Related]
14. Endogenous human prolactin and not exogenous human prolactin induces estrogen receptor alpha and prolactin receptor expression and increases estrogen responsiveness in breast cancer cells.
Gutzman JH; Miller KK; Schuler LA
J Steroid Biochem Mol Biol; 2004 Jan; 88(1):69-77. PubMed ID: 15026085
[TBL] [Abstract][Full Text] [Related]
15. Impaired turnover of prolactin receptor contributes to transformation of human breast cells.
Plotnikov A; Varghese B; Tran TH; Liu C; Rui H; Fuchs SY
Cancer Res; 2009 Apr; 69(7):3165-72. PubMed ID: 19276348
[TBL] [Abstract][Full Text] [Related]
16. The Role of Prolactin in Bone Metastasis and Breast Cancer Cell-Mediated Osteoclast Differentiation.
Sutherland A; Forsyth A; Cong Y; Grant L; Juan TH; Lee JK; Klimowicz A; Petrillo SK; Hu J; Chan A; Boutillon F; Goffin V; Egan C; Tang PA; Cai L; Morris D; Magliocco A; Shemanko CS
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26586670
[TBL] [Abstract][Full Text] [Related]
17. Prolactin as a local growth promoter in patients with breast cancer: GCRI experience.
Bhatavdekar JM; Patel DD; Shah NG; Vora HH; Suthar TP; Ghosh N; Chikhlikar PR; Trivedi TI
Eur J Surg Oncol; 2000 Sep; 26(6):540-7. PubMed ID: 11034803
[TBL] [Abstract][Full Text] [Related]
18. Prolactin in breast and prostate cancer: molecular and genetic perspectives.
Jacobson EM; Hugo ER; Borcherding DC; Ben-Jonathan N
Discov Med; 2011 Apr; 11(59):315-24. PubMed ID: 21524385
[TBL] [Abstract][Full Text] [Related]
19. From bench to bedside: future potential for the translation of prolactin inhibitors as breast cancer therapeutics.
Clevenger CV; Zheng J; Jablonski EM; Galbaugh TL; Fang F
J Mammary Gland Biol Neoplasia; 2008 Mar; 13(1):147-56. PubMed ID: 18246318
[TBL] [Abstract][Full Text] [Related]
20. Regulation of prolactin receptor levels and activity in breast cancer.
Swaminathan G; Varghese B; Fuchs SY
J Mammary Gland Biol Neoplasia; 2008 Mar; 13(1):81-91. PubMed ID: 18204982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
